Cell: An effective antibody against the new coronavirus has been identified to protect infected hamsters from lung lesions.

!--,2020 / / --- New Coronavirus SARS-CoV-2 causes coronavirus disease (COVID-19) in 2019 and is now raging around the world.
a new study, researchers from the German Center for Neurodegenerative Diseases and berlin's Schalette School of Medicine identified highly effective antibodies against SARS-CoV-2 and are working on a passive immune strategy.
process, they also found that some SARS-CoV-2 antibodies bind to tissue samples from multiple organs, which can trigger adverse side effects.
the results of the study, published online September 23, 2020 in the journal Cell, are titled "A therapeutic non-self-reactive SARS-CoV-2 antibody protects from lung pathology a COVID-19 hamster model".
images from CC0 Public Domain.
, scientists isolated nearly 600 different antibodies from the blood of people who beat COVID-19.
laboratory tests, they were able to narrow down to several antibodies that were particularly effective in binding to the virus.
, they used cell cultures to artificially create these antibodies.
crystallological analysis showed that these identified so-called meso-antibodies bind to the virus, preventing it from entering cells and proliferating.
addition, antibodies' recognition of the virus helps immune cells eliminate it. Dr. Jakob Kreye of the German Center for Neurodegenerative Diseases, co-lead author of the
paper, said the study of hamsters, who, like humans, were susceptible to SARS-CoV-2 infection, confirmed the effectiveness of the antibodies chosen: "If these antibodies were given after infection, hamsters would have mild symptoms of disease at most."
if these antibodies were given before infection, hamster animals would not get sick.
" antibodies used for passive immunity have a long history of treating infectious diseases with antibodies.
for COVID-19, this method is also being studied by giving plasma extracted from the blood of recovered patients.
when plasma is given, the provider antibodies in the plasma are also transferred to the patient's body.
, "Ideally, the most effective antibodies are produced in a controlled manner on an industrial scale and have stable quality," said Dr. Momsen Reincke, co-lead author of the paper.
's what we're after.
"Our three antibodies are particularly promising for clinical development," explains Professor Harald Prüss, head of the research team at the German Center for Neurodegenerative Diseases.
by using these antibodies, we have begun to develop passive immune strategies against SARS-CoV-2.
" is also a potential application for preventive protection of healthy individuals who come into contact with infected people, in addition to treating patients.
how long this protection lasts will be investigated in clinical studies.
, "This is because, unlike active immune strategies, passive immunity involves giving ready-made antibodies that degrade over time."
", passive immunity provides less protection than active immunity provides long-lasting protection.
, however, the effects of passive immunity are almost immediate, and the effects of active immunity must be gradually established first.
"it is best to provide both treatment options in order to respond flexibly to the situation.
"Modern technology Kraye, Reincke, Prüss and their colleagues often study autoimmune diseases in the brain, in which antibodies mistakenly attack neurons.
, "However, in the face of the COVID-19 pandemic, it is clear that our resources can also be used in other ways, " says Professor Prüss.
"For the current research project, these researchers will benefit from a project funded by the Helmholtz Society: Bao Bab Innovation Lab."
framework, they are developing and improving technologies for the designation and production of antibodies.
, "Today, we are working with our industry partners to establish conditions for the most efficient mass production of the antibodies we have identified."
next step is clinical trials, which are tested in humans.
, however, is not expected to be done until the end of the year at the earliest.
plans to address this have already begun.
" potential side effects in the study, the researchers further found that some particularly effective antibodies that bind to coronavirus SARS-CoV-2 attach to proteins in the brain, heart muscle, and blood vessels.
tests on tissue samples from mice, several of the neutral antibodies showed this cross-reactivity.
, they are excluded from passive immunity.
these antibodies bind not only to the virus, but also to proteins in the body that are not related to the virus, " says Professor Prüss.
further research is needed to analyze whether the tissue could be targeted by its own immune system.
" these laboratory findings are also applicable to humans is not yet predictable.
, "On the one hand, we need to be vigilant so that we can detect any autoimmune responses that may occur during and during COVID-19 onset," he said.
, on the other hand, these findings help ensure the development of safer vaccines.
" (bioon.com) Reference: JakobKreye et al. A therapeutic non-self-reactive SARS-CoV-2 antibody protects from pathology in a COVID-19 hamster model. Cell, 2020, doi:10.1016/j.cell.2020.09.049.COVID-19: German scientists lay basis for a passive feed title !--.